Omeros Corporation (OMER) to Release Quarterly Earnings on Tuesday
Omeros Corporation (NASDAQ:OMER) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.12. The business had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $14.63 million. The firm’s quarterly revenue was up 71.5% on a year-over-year basis. During the same period last year, the firm earned ($0.32) earnings per share. On average, analysts expect Omeros Corporation to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of Omeros Corporation (OMER) opened at $14.94 on Monday. The company has a current ratio of 2.15, a quick ratio of 2.11 and a debt-to-equity ratio of -1.49.
A number of research firms have recently commented on OMER. Cowen and Company cut Omeros Corporation from an “outperform” rating to a “market perform” rating in a research report on Thursday. Maxim Group set a $24.00 target price on Omeros Corporation and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Wedbush reiterated an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a research report on Friday, August 18th. Zacks Investment Research upgraded Omeros Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $19.00 target price (up previously from $15.00) on shares of Omeros Corporation in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $34.83.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.